Skip to content
etf.net

BBC

GradeDNew York Stock Exchange Arca

Virtus Biotech Clinical Trials ETF

Virtus · Inception 2014-12-16

$46.49−3.40 (−6.81%)

As of Sep 23, 2026, 2:20 PM EDT

Intraday session: down, 30 prints from 49.89 to 46.49. Range 46.43 to 49.81. Use the arrow keys to read each point.$47.00$48.00$49.00$50.0010 AM12 PM2 PM4 PM
Expense ratio
0.65%
Fund size
$50M
1Y return
+140.0%
Yield · Last 12 months
Data unavailable
Holdings
198
Volume · 30D
0M sh
NAV per share
$52.95
52W range
low $21.83high $54.95

The ETF.net BBC Grade

D

37/ 100

Confidence Medium

Six-pillar profile for BBC. Scores out of 100: Cost 9, Risk 39, Mission 49, Tradability 32, Holdings 92, Durability 43. Strongest: Holdings (92). Weakest: Cost (9). Leans toward Holdings.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 37 of 100 sits in the D band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    FScore 9
    —

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    CScore 49
    —

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    DScore 39
    —

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    DScore 32
    —

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    AScore 92
    —

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    CScore 43
    —

Graded as of Aug 18, 2026

Our read on BBC

ETF.net Research

DMost biotech funds blend approved-drug cash machines with science projects. BBC keeps only the science projects: US-listed biotechs whose lead drug is still in clinical trials, spread across roughly 200 names.

Stated mandate

The Fund seeks to track, before fees and expenses, the investment results of the LifeSci Biotechnology Clinical Trials Index. The Index comprises U.S.-listed biotechnology stocks with a lead drug in clinical-stage development.

Why people hold it

  1. 01A genuinely narrow mandate: the index takes U.S.-listed biotechs with a lead drug in clinical-stage development, so commercial-stage giants stay out.
  2. 02Roughly 200 holdings, so one failed readout is a dent, not the whole fund.
  3. 03The basket lines up tightly with what the prospectus says it owns, one of the cleaner mandate-to-portfolio matches in biotech.
  4. 04Running since 2014, which makes it one of the longer-lived pure clinical-stage plays rather than a recent theme launch.

Worth knowing

  1. 01At 0.65% a year it costs more than the typical biotech fund, and more than broad peers like XBI (0.35%) and IBB (0.44%).
  2. 02Small asset base and thin trading, so spreads can widen and large orders move the price.
  3. 03Pre-approval biotech is binary by nature, and on our review the fund sits in the lower tier of its biotech peer group overall.

BBC Holdings

As of Aug 19, 2026, 3:00 AM
Asset class
Stocks
Holdings
198
Top-10 weight
12%
Largest holding
TRAX1.5%

Sectors

  • Health Care100.0%

Geography

  • United States90.08%
  • Netherlands2.32%
  • Canada2.05%
  • Ireland1.54%
  • United Kingdom1.31%
  • Switzerland1.27%
The fund’s holdings, weight-ordered — page 1 of 2.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001TRAXFirst Tracks Biotherapeutics Inc1.52%—$768K60
002ABCLAbCellera Biologics Inc1.32%—$664K12
003MNPRMonopar Therapeutics Inc1.20%—$606K33
004MBXMBX Biosciences Inc1.18%—$597K68
005XNCRXencor Inc1.15%—$583K85
006ATAIAtaiBeckley Inc1.14%—$574K56
007DFTXDefinium Therapeutics Inc1.13%—$568K58
008QUREuniQure NV1.07%—$541K18
009RGNXREGENXBIO Inc1.05%—$529K55
010SLSSELLAS Life Sciences Group Inc1.02%—$516K47
011REPLReplimune Group Inc1.01%—$512K52
012FDMT4D Molecular Therapeutics Inc1.01%—$512K55
013LBRXLB Pharmaceuticals Inc1.00%—$506K43
014ORICORIC Pharmaceuticals Inc1.00%—$503K63
015ORKAOruka Therapeutics Inc0.99%—$501K70

Showing 1–15 of 30 holdings

BBC Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Performance data is unavailable.

Returns run to the last market close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BBC. Periods over one year show the average yearly return.
PeriodBBC
Year to dateHistory unavailable—
1 monthHistory unavailable—
3 monthsHistory unavailable—
1 yearHistory unavailable—
3 yearsHistory unavailable—per year
5 yearsHistory unavailable—per year
10 yearsHistory unavailable—per year

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual return data is unavailable.

BBC in the news

BBC Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date.
Data unavailableLast 12 months
Payout per share
Data unavailableLast 12 months

Distribution data unavailable.

BBC Risk

How much the fund’s monthly returns vary, scaled to a year.
—
No data available
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
—
No data available
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
—
No data available
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.18
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

BBC Cost

Expense Ratio
0.65%